Recursion Pharmaceuticals, Inc.
NASDAQ:RXRXBiotechnology
+$0.04 today
- Market cap
- $1.76B
- Beta
- 1.00
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$1.06
Volume 41.13M
Average 15.60M
RXRX Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Recursion Pharmaceuticals, Inc.NASDAQ: RXRX
Net Margin · Q2 FY2026 · quarter ended Jun 2026
Net margin narrows to -1708.0%
Net margin was -1708.0% in Q2 FY2026, down 808.2 pp from a year earlier. On a trailing-twelve-month basis it was -945.9%, up 61.1 pp year over year. Over 3 fiscal years it narrowed by 259.8 pp.
Context
- Net margin widened in 0 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 6 analysts of -998.0% for the fiscal year ending Dec 2026, down from -863.4% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -1708.0%+107.6 pp QoQ
- Last fiscal yearDec 2025
- -863.4%-75.3 pp YoY
- LTMJun 2026
- -945.9%+61.1 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -808.2 pp | +2332.1 pp | +3140.3 pp |
| 1 year | -75.3 pp | -134.6 pp | -59.3 pp |
| 3 years | -259.8 pp | -29.5 pp | +230.4 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -863.4%
- Year-over-year change
- -75.3pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -863.4% | -75.3pp |
| FY2024 | 2024-12-31 | -788.0% | -40.3pp |
| FY2023 | 2023-12-31 | -747.7% | -144.2pp |
| FY2022 | 2022-12-31 | -603.5% | +1261.3pp |
| FY2021 | 2021-12-31 | -1864.8% | — |
Net Margin vs competitors
How RXRX compares with its peers on the latest reported figures
- RXRX's LTM Jun 2026 net margin of -945.9% is the 2nd highest of the 4 companies compared; the peer median is -2763.6%.
- Its year-over-year change of +61.1 pp is the 2nd highest of 3, against a peer median of +160.5 pp.
- Over three fiscal years its change of -259.8 pp compares with a peer median of +19235.6 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -612.7% | -643.7 pp | — | |
| LTM Jun 2026 | -945.9% | +61.1 pp | -259.8 pp | |
| LTM Jun 2026 | -2763.6% | +964.8 pp | +19235.6 pp | |
| LTM Jun 2026 | -14191.2% | — | — | |
| Peer median (excluding RXRX) | -2763.6% | +160.5 pp | +19235.6 pp | |
Competitors are the stored peer set for RXRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10M | 39.68M | 43.88M | 58.84M | 74.68M |
| Cost of Revenue | 0 | 48.28M | 42.59M | 45.24M | 120.95M |
| Gross Profit | 10M | (8.59M) | 1.29M | 13.6M | (46.27M) |
| Gross Margin | 100.0% | -21.7% | 2.9% | 23.1% | -62.0% |
| Research & Development | 135.27M | 155.7M | 241.23M | 314.42M | 425.27M |
| Selling, General & Admin | 57.68M | 81.6M | 110.82M | 178.18M | 176.59M |
| Operating Expenses | 192.78M | 237.13M | 351.35M | 492.61M | 601.86M |
| Depreciation & Amortization | 8.41M | 11.76M | 24.4M | 36.49M | 83.7M |
| EBITDA | (175.12M) | (227.67M) | (307.63M) | (426.72M) | (559.38M) |
| EBITDA Margin | -1751.2% | -573.7% | -701.1% | -725.2% | -749.0% |
| Operating Income | (182.78M) | (245.73M) | (350.06M) | (479M) | (648.13M) |
| Operating Margin | -1827.8% | -619.3% | -797.8% | -814.1% | -867.9% |
| Interest Income | 73K | 6.25M | 19.12M | 15.76M | 22.79M |
| Interest Expense | 2.95M | 55K | 97K | 1.57M | 1.81M |
| Other Income / Expenses | (3.7M) | 6.25M | 17.93M | 14.22M | 3.24M |
| Income Before Tax | (186.48M) | (239.48M) | (332.13M) | (464.79M) | (644.9M) |
| Pre-Tax Margin | -1864.8% | -603.5% | -757.0% | -789.9% | -863.5% |
| Income Tax Expense | 0 | 0 | (4.06M) | (1.13M) | (136K) |
| Net Income | (186.48M) | (239.48M) | (328.07M) | (463.66M) | (644.76M) |
| Net Margin | -1864.8% | -603.5% | -747.7% | -788.0% | -863.4% |
| EPS (Basic) | (1.05) | (1.36) | (1.58) | (1.69) | (1.44) |
| EPS (Diluted) | (1.05) | (1.36) | (1.58) | (1.69) | (1.44) |
| Weighted Avg Shares | 170.27M | 175.54M | 207.85M | 274.21M | 447.45M |
| Weighted Avg Shares (Diluted) | 170.27M | 175.54M | 207.85M | 274.21M | 447.45M |
Recursion Pharmaceuticals, Inc.
NASDAQ:RXRX
Intrinsic Alpha fair value
Locked
Current Price
$2.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.